- Home
- TRC vs MNMD Comparison
TRC vs MNMD Comparison
Compare TRC & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRC
- MNMD
- Stock Information
- Founded
- TRC 1843
- MNMD 2019
- Country
- TRC United States
- MNMD United States
- Employees
- TRC N/A
- MNMD N/A
- Industry
- TRC Real Estate
- MNMD Pharmaceuticals and Biotechnology
- Sector
- TRC Finance
- MNMD Health Care
- Exchange
- TRC Nasdaq
- MNMD Nasdaq
- Market Cap
- TRC 463.5M
- MNMD 541.7M
- IPO Year
- TRC N/A
- MNMD N/A
- Fundamental
- Price
- TRC $16.55
- MNMD $7.02
- Analyst Decision
- TRC
- MNMD Strong Buy
- Analyst Count
- TRC 0
- MNMD 8
- Target Price
- TRC N/A
- MNMD $26.29
- AVG Volume (30 Days)
- TRC 104.4K
- MNMD 1.1M
- Earning Date
- TRC 08-05-2025
- MNMD 08-12-2025
- Dividend Yield
- TRC N/A
- MNMD N/A
- EPS Growth
- TRC 298.28
- MNMD N/A
- EPS
- TRC 0.08
- MNMD N/A
- Revenue
- TRC $42,689,000.00
- MNMD N/A
- Revenue This Year
- TRC $0.64
- MNMD N/A
- Revenue Next Year
- TRC N/A
- MNMD N/A
- P/E Ratio
- TRC $207.56
- MNMD N/A
- Revenue Growth
- TRC 7.04
- MNMD N/A
- 52 Week Low
- TRC $14.71
- MNMD $4.70
- 52 Week High
- TRC $19.82
- MNMD $10.44
- Technical
- Relative Strength Index (RSI)
- TRC 53.63
- MNMD 46.62
- Support Level
- TRC $16.06
- MNMD $6.64
- Resistance Level
- TRC $16.55
- MNMD $7.34
- Average True Range (ATR)
- TRC 0.36
- MNMD 0.45
- MACD
- TRC 0.04
- MNMD -0.12
- Stochastic Oscillator
- TRC 77.12
- MNMD 19.61
About TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).